首页> 美国卫生研究院文献>Scientific Reports >Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology
【2h】

Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology

机译:细针穿刺细胞学技术获得的肺腺癌标本的分子诊断的下一代测序

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Identification of multi-gene variations has led to the development of new targeted therapies in lung adenocarcinoma patients, and identification of an appropriate patient population with a reliable screening method is the key to the overall success of tumor targeted therapies. In this study, we used the Ion Torrent next-generation sequencing (NGS) technique to screen for mutations in 89 cases of lung adenocarcinoma metastatic lymph node specimens obtained by fine-needle aspiration cytology (FNAC). Of the 89 specimens, 30 (34%) were found to harbor epidermal growth factor receptor (EGFR) kinase domain mutations. Seven (8%) samples harbored KRAS mutations, and three (3%) samples had BRAF mutations involving exon 11 (G469A) and exon 15 (V600E). Eight (9%) samples harbored PIK3CA mutations. One (1%) sample had a HRAS G12C mutation. Thirty-two (36%) samples (36%) harbored TP53 mutations. Other genes including APC, ATM, MET, PTPN11, GNAS, HRAS, RB1, SMAD4 and STK11 were found each in one case. Our study has demonstrated that NGS using the Ion Torrent technology is a useful tool for gene mutation screening in lung adenocarcinoma metastatic lymph node specimens obtained by FNAC, and may promote the development of new targeted therapies in lung adenocarcinoma patients.
机译:多基因变异的鉴定已导致在肺腺癌患者中开发出新的靶向治疗方法,用可靠的筛选方法鉴定合适的患者人群是肿瘤靶向治疗方法总体成功的关键。在这项研究中,我们使用离子洪流下一代测序(NGS)技术筛选了89例通过细针穿刺细胞学(FNAC)获得的肺腺癌转移性淋巴结标本中的突变。在89个样本中,有30个(34%)被发现具有表皮生长因子受体(EGFR)激酶结构域突变。七个(8%)样本具有KRAS突变,三个(3%)样本具有涉及外显子11(G469A)和外显子15(V600E)的BRAF突变。八个(9%)样本包含PIK3CA突变。一个(1%)样品具有HRAS G12C突变。三十二(36%)个样本(36%)带有TP53突变。在一例中发现了其他基因,包括APC,ATM,MET,PTPN11,GNAS,HRAS,RB1,SMAD4和STK11。我们的研究表明,使用离子洪流技术的NGS是通过FNAC获得的肺腺癌转移性淋巴结标本进行基因突变筛查的有用工具,并可能促进肺腺癌患者靶向治疗的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号